Adverse Drug Reactions from Real-World Data in Inflammatory Bowel Disease Patients in the IBDREAM RegistryFrank Hoentjen, Eline L. Giraud, Pepijn W. A. Thomas et al.|Drug Safety|2021Cited by 20
Discrepancy between patient‐ and healthcare provider‐reported adverse drug reactions in inflammatory bowel disease patients on biological therapyPepijn W. A. Thomas, Frank Hoentjen, Tessa E H Römkens et al.|United European Gastroenterology Journal|2021Cited by 16
Real‐world reported adverse events related to systemic immunomodulating therapy in patients with atopic dermatitis: Results from the <scp>TREAT NL</scp> (<scp>TREatment</scp> of <scp>ATopic</scp> eczema, the Netherlands) registryAnnelie H. Musters, Phyllis I. Spuls, Wouter Ouwerkerk et al.|Journal of the European Academy of Dermatology and Venereology|2023Cited by 14
Inflammatory bowel disease patients provide reliable self‐reported medical information: A multicentre prospective pharmacovigilance monitoring systemPepijn W. A. Thomas, Rachel West, Maurice G. Rüssel et al.|Pharmacoepidemiology and Drug Safety|2020Cited by 10
P330 Inflammatory Bowel Disease (IBD) patients frequently report adverse drug reactions during biologic therapy: A multicentre, prospective, patient-reported pharmacovigilance monitoring systemPepijn W. A. Thomas, Frank Hoentjen, Robert West et al.|Journal of Crohn s and Colitis|2020Cited by 3